Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25975362 | 0.97 | RAB9A (0.50) | RAB9APKMTSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL20103706 | 0.81 | THRB (0.39) | RAB9APKMTSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL5104779 | 0.78 | PKM (0.56) | RAB9APKMTSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL20416291 | 0.77 | THRB (0.42) | RAB9APKMTSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL23822907 | 0.75 | THRB (0.41) | RAB9ATSHRHSD17B10THRB | |
| SCHEMBL4449130 | 0.75 | THRB (0.37) | RAB9APKMTSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL27402648 | 0.75 | THRB (0.41) | RAB9ATSHRHSD17B10THRB | |
| Hydrochloric Acid SCHEMBL26979715 | 0.75 | THRB (0.41) | RAB9APKMTSHRHSD17B10THRB | |
| SCHEMBL12858855 | 0.75 | ALDH1A1 (0.70) | RAB9APKMTSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL12858018 | 0.75 | RAB9A (0.69) | RAB9APKMTSHRHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | RAB9A 4198/4885PKM 3506/4885TSHR 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.